目的探讨乌司他丁(UTI)对脂多糖(LPS)致大鼠急性肺损伤(ALI)组织糖皮质激素受体(GR)的影响,并了解其可能机制。方法清洁级成年雄性SD大鼠54只,随机分为3组:空白对照组(Con组,n=18),LPS组(n=18),脂多糖+乌司他丁组(LPS+UTI组,n=18)。各...目的探讨乌司他丁(UTI)对脂多糖(LPS)致大鼠急性肺损伤(ALI)组织糖皮质激素受体(GR)的影响,并了解其可能机制。方法清洁级成年雄性SD大鼠54只,随机分为3组:空白对照组(Con组,n=18),LPS组(n=18),脂多糖+乌司他丁组(LPS+UTI组,n=18)。各组又按照不同的时间点被分为4 h、8 h、12 h三个亚组。在各时间点处死大鼠,利用Western blot检测大鼠肺组织中GR的表达,实时荧光定量PCR检测GR m RNA的表达,同时酶联免疫吸附法(ELISA)检测肺组织匀浆液中肿瘤坏死因子(TNF)-α和白细胞介素(IL)-10的浓度以及肺组织病理学的变化。结果与对照组相比,LPS组GR蛋白表达在各时间点降低(P<0.05),LPS+UTI组GR蛋白在各时间点的表达水平高于LPS组,低于Con组(P<0.05);与对照组相比,LPS组GR m RNA表达降低(P<0.05),LPS+UTI组GR m RNA在各时间点的表达水平略高于LPS组(P>0.05),低于Con组(P<0.05);与对照组相比,LPS组TNF-α的表达在各时间点升高(P<0.05),LPS+UTI组TNF-α的表达水平在各时间点低于LPS组,高于Con组(P<0.05);与对照组相比,LPS组IL-10的表达在各时间点升高(P<0.05),LPS+UTI组IL-10的表达水平在各时间点高于LPS组(P<0.05)。组织病理学检查显示:LPS组肺组织见肺泡结构破坏,炎性细胞浸润,肺泡间隔增宽,出血,水肿,LPS+UTI组肺组织病理损害较LPS组明显减轻。结论 UTI能提高GR的表达;TNF-α和IL-10出现高峰的时间不同。展开更多
Large interventional studies have shown that statins may reduce the incidence of type 2 diabetes mellitus. However, it is uncertain whether short-term statin therapy can affect insulin sensitivity in patients with the...Large interventional studies have shown that statins may reduce the incidence of type 2 diabetes mellitus. However, it is uncertain whether short-term statin therapy can affect insulin sensitivity in patients with the metabolic syndrome. We evaluated the effect of atorvastatin(10 mg/day) in 10 insulin-resistant subjects(age 40±12 years, body mass index 33.6±5.2 kg/m2, triglycerides 2.84±1.99 mmol/L[249±175mg/dl], glucose 6.06±0.67 mmol/L[109±12 mg/dl]) using the homeostasis model assessment(HOMA) index(parameter of insulin resistance derived from fasting glucose and fasting insulin concentrations; 5.7±2.6) in a randomized placebo-controlled, double-blind, crossover study. Subjects were randomized to receive placebo or atorvastatin, each given for 6 weeks separated by a 6-week wash-out period. At the beginning and end of each treatment phase, the patients underwent an oral glucose tolerance test, a 72-hour continuous glucose measurement, and a detailed lipid determination, including a standardized fat tolerance test. Compared with placebo, atorvastatin resulted in a significant(p=0.05) reduction in the HOMA index(-21%), fasting C-peptides(-18%), glucose(area under the curve during the oral glucose tolerance test,-7%), and a borderline(p=0.08) reduction of insulin(-18%). The parameters derived from the continuous 72-hour glucose monitoring did not change. A significant reduction also occurred in the total and low-density lipoprotein cholesterol concentrations, although the fasting and postprandial triglyceride concentrations did not change significantly. However, we found a significant correlation between atorvastatin-induced changes in the HOMA and baseline HOMA and between the atorvastatin-induced changes in triglycerides and insulin concentrations. The free-fatty acid, interleukin-6, and high sensitivity C-reactive protein concentrations did not change. Our data indicated that in insulin-resistant, nondiabetic subjects, 6 weeks of atorvastatin(10 mg/day) resulted in significant improvement in insulin sens展开更多
文摘目的探讨乌司他丁(UTI)对脂多糖(LPS)致大鼠急性肺损伤(ALI)组织糖皮质激素受体(GR)的影响,并了解其可能机制。方法清洁级成年雄性SD大鼠54只,随机分为3组:空白对照组(Con组,n=18),LPS组(n=18),脂多糖+乌司他丁组(LPS+UTI组,n=18)。各组又按照不同的时间点被分为4 h、8 h、12 h三个亚组。在各时间点处死大鼠,利用Western blot检测大鼠肺组织中GR的表达,实时荧光定量PCR检测GR m RNA的表达,同时酶联免疫吸附法(ELISA)检测肺组织匀浆液中肿瘤坏死因子(TNF)-α和白细胞介素(IL)-10的浓度以及肺组织病理学的变化。结果与对照组相比,LPS组GR蛋白表达在各时间点降低(P<0.05),LPS+UTI组GR蛋白在各时间点的表达水平高于LPS组,低于Con组(P<0.05);与对照组相比,LPS组GR m RNA表达降低(P<0.05),LPS+UTI组GR m RNA在各时间点的表达水平略高于LPS组(P>0.05),低于Con组(P<0.05);与对照组相比,LPS组TNF-α的表达在各时间点升高(P<0.05),LPS+UTI组TNF-α的表达水平在各时间点低于LPS组,高于Con组(P<0.05);与对照组相比,LPS组IL-10的表达在各时间点升高(P<0.05),LPS+UTI组IL-10的表达水平在各时间点高于LPS组(P<0.05)。组织病理学检查显示:LPS组肺组织见肺泡结构破坏,炎性细胞浸润,肺泡间隔增宽,出血,水肿,LPS+UTI组肺组织病理损害较LPS组明显减轻。结论 UTI能提高GR的表达;TNF-α和IL-10出现高峰的时间不同。
文摘Large interventional studies have shown that statins may reduce the incidence of type 2 diabetes mellitus. However, it is uncertain whether short-term statin therapy can affect insulin sensitivity in patients with the metabolic syndrome. We evaluated the effect of atorvastatin(10 mg/day) in 10 insulin-resistant subjects(age 40±12 years, body mass index 33.6±5.2 kg/m2, triglycerides 2.84±1.99 mmol/L[249±175mg/dl], glucose 6.06±0.67 mmol/L[109±12 mg/dl]) using the homeostasis model assessment(HOMA) index(parameter of insulin resistance derived from fasting glucose and fasting insulin concentrations; 5.7±2.6) in a randomized placebo-controlled, double-blind, crossover study. Subjects were randomized to receive placebo or atorvastatin, each given for 6 weeks separated by a 6-week wash-out period. At the beginning and end of each treatment phase, the patients underwent an oral glucose tolerance test, a 72-hour continuous glucose measurement, and a detailed lipid determination, including a standardized fat tolerance test. Compared with placebo, atorvastatin resulted in a significant(p=0.05) reduction in the HOMA index(-21%), fasting C-peptides(-18%), glucose(area under the curve during the oral glucose tolerance test,-7%), and a borderline(p=0.08) reduction of insulin(-18%). The parameters derived from the continuous 72-hour glucose monitoring did not change. A significant reduction also occurred in the total and low-density lipoprotein cholesterol concentrations, although the fasting and postprandial triglyceride concentrations did not change significantly. However, we found a significant correlation between atorvastatin-induced changes in the HOMA and baseline HOMA and between the atorvastatin-induced changes in triglycerides and insulin concentrations. The free-fatty acid, interleukin-6, and high sensitivity C-reactive protein concentrations did not change. Our data indicated that in insulin-resistant, nondiabetic subjects, 6 weeks of atorvastatin(10 mg/day) resulted in significant improvement in insulin sens
